HSV-gB2 498-505
Need Assistance?
  • US & Canada:
    +
  • UK: +

HSV-gB2 498-505

* Please kindly note that our products are not to be used for therapeutic purposes and cannot be sold to patients.

HSV-gB2 498-505 is an immunodominant epitope derived from the herpes simplex virus (HSV) glycoprotein B residues 498-505, and is a cytotoxic T lymphocyte (CTL) recognition epitope with H-2kB restriction and HSV-1/2 cross-reaction.

Category
Peptide Inhibitors
Catalog number
BAT-009249
CAS number
149997-91-1
Molecular Formula
C41H67N11O13
Molecular Weight
922.04
IUPAC Name
(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-amino-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-methylpentanoyl]amino]-4-carboxybutanoyl]amino]-3-phenylpropanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-4-methylpentanoic acid
Synonyms
H-Ser-Ser-Ile-Glu-Phe-Ala-Arg-Leu-OH; L-seryl-L-seryl-L-isoleucyl-L-alpha-glutamyl-L-phenylalanyl-L-alanyl-L-arginyl-L-leucine
Appearance
White or Off-white Lyophilized Powder
Purity
≥95%
Density
1.4±0.1 g/cm3
Sequence
SSIEFARL
Storage
Store at -20°C
Solubility
Soluble in DMSO
InChI
InChI=1S/C41H67N11O13/c1-6-22(4)32(52-38(62)30(20-54)51-34(58)25(42)19-53)39(63)48-27(14-15-31(55)56)36(60)49-28(18-24-11-8-7-9-12-24)37(61)46-23(5)33(57)47-26(13-10-16-45-41(43)44)35(59)50-29(40(64)65)17-21(2)3/h7-9,11-12,21-23,25-30,32,53-54H,6,10,13-20,42H2,1-5H3,(H,46,61)(H,47,57)(H,48,63)(H,49,60)(H,50,59)(H,51,58)(H,52,62)(H,55,56)(H,64,65)(H4,43,44,45)/t22-,23-,25-,26-,27-,28-,29-,30-,32-/m0/s1
InChI Key
UBVOHDHFHIMSCO-YWZBYMRGSA-N
Canonical SMILES
CCC(C)C(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CC=CC=C1)C(=O)NC(C)C(=O)NC(CCCN=C(N)N)C(=O)NC(CC(C)C)C(=O)O)NC(=O)C(CO)NC(=O)C(CO)N
1. Hemangioma-related syndromes
Manuel Valdebran, Lara Wine Lee Curr Opin Pediatr. 2020 Aug;32(4):498-505. doi: 10.1097/MOP.0000000000000925.
Purpose of review: There is a growing understanding of complications and anomalies associated with infantile hemangiomas. The current review will discuss recent clinical advances in syndromes associated with segmental hemangiomas, including PHACE and LUMBAR syndrome. In addition, the importance of recognizing visceral hemangiomatosis is highlighted. Recent findings: Ongoing longitudinal studies of PHACE and LUMBAR syndromes associated with segmental infantile hemangiomas have led to improved diagnosis and recommendations for screening for associated anomalies. Characterization of a growing spectrum of associated anomalies as well as better classification of at-risk patients will improve diagnosis and outcomes. In addition, visceral hemangiomatosis recognition and understanding of the potential association with consumptive hypothyroidism will improve initiation of appropriate screening. Summary: Clinicians should be aware of infantile hemangiomas associated with potential syndromic complications and recognize the need to initiate appropriate work-up. Segmental hemangiomas of the head and neck region may indicate a risk of PHACE syndrome and associated developmental anomalies. Although LUMBAR syndrome is the association of lower body segmental hemangioma with developmental anomalies. Visceral hemangiomas most commonly affect the liver and may be associated with complications such as consumptive hypothyroidism and heart failure.
2. The mechanisms of rejection in solid organ transplantation
Emanuele Cozzi, Anna Colpo, Giustina De Silvestro Transfus Apher Sci. 2017 Aug;56(4):498-505. doi: 10.1016/j.transci.2017.07.005. Epub 2017 Jul 8.
Organ transplantation represents the preferred treatment option for many patients in terminal organ failure. The half-life of transplanted organs, however, is still far from being satisfactory with the vast majority of the organs failing within the first two decades following transplantation. At this stage, it has become apparent that rejection (prevalently mediated by humoral events) remains the primary cause of graft loss after the first year. In this light, studies are underway to better comprehend the immune events underlying graft rejection and novel immunosuppressive strategies are being explored. In this context, therapeutic apheresis techniques, that include therapeutic plasma exchange (TPE), immunoadsorption (IA) and extracorporeal photochemotherapy (ECP), represent an important adjunct in the current immunosuppressive armamentarium. This article briefly reviews our current understanding of the immune process underlying rejection of a solid organ transplant and describes the principal areas of application of therapeutic apheresis techniques in transplantation.
3. Position statement on youth resistance training: the 2014 International Consensus
Rhodri S Lloyd, et al. Br J Sports Med. 2014 Apr;48(7):498-505. doi: 10.1136/bjsports-2013-092952. Epub 2013 Sep 20.
The current manuscript has been adapted from the official position statement of the UK Strength and Conditioning Association on youth resistance training. It has subsequently been reviewed and endorsed by leading professional organisations within the fields of sports medicine, exercise science and paediatrics. The authorship team for this article was selected from the fields of paediatric exercise science, paediatric medicine, physical education, strength and conditioning and sports medicine.
Online Inquiry
Verification code
Inquiry Basket